BioSpace News Archive

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2019 will be released after the market closes on Monday, March 16.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2019.

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2019.

Rite Aid Corporation announced the settlement of its previously announced offer to exchange up to $600 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2023 for newly issued 7.500% Senior Secured Notes due 2025.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 first quarter ended December 31, 2019.

Already the leader in CRISPR-based disease detection, the latest round will drive Mammoth’s robust platform for protein discovery to extend into gene-editing and therapeutics applications.

Using pseudo-random speckle patterns is an efficient way to image targets, but most approaches require bulky, expensive, complex and slow machinery.

Centene Corporation announced that it has priced its offering of $2,000,000,000 aggregate principal amount of 3.375% of new senior notes due 2030.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock.

R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced it expects to release financial results for the three months and full year ended December 31, 2019 before market open on Thursday, February 20, 2020.